Venus Concept (NASDAQ:VERO) versus TransMedics Group (NASDAQ:TMDX) Head-To-Head Review

TransMedics Group (NASDAQ:TMDX) and Venus Concept (NASDAQ:VERO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Volatility and Risk

TransMedics Group has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, Venus Concept has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500.

Profitability

This table compares TransMedics Group and Venus Concept’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TransMedics Group	31.43%	30.17%	11.39%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Analyst Ratings

This is a breakdown of current recommendations for TransMedics Group and Venus Concept, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0	5	6	0	2.55
Venus Concept	1	0	0	0	1.00

TransMedics Group presently has a consensus target price of $152.33, indicating a potential upside of 23.37%. Given TransMedics Group’s stronger consensus rating and higher possible upside, equities analysts clearly believe TransMedics Group is more favorable than Venus Concept.

Earnings & Valuation

This table compares TransMedics Group and Venus Concept”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49 million	6.99	$190.29 million	$4.90	25.20
Venus Concept	$58.88 million	0.01	-$47.00 million	($48.84)	-0.01

TransMedics Group has higher revenue and earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 7.0% of TransMedics Group shares are owned by insiders. Comparatively, 28.0% of Venus Concept shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

TransMedics Group beats Venus Concept on 13 of the 14 factors compared between the two stocks.

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

About Venus Concept

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.